about
A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New GuineaUpdated projections of future vCJD deaths in the UKvCJD risk in the Republic of IrelandEpidemiological evidence of higher susceptibility to vCJD in the youngA review of back-calculation techniques and their potential to inform mitigation strategies with application to non-transmissible acute infectious diseasesEarly efforts in modeling the incubation period of infectious diseases with an acute course of illness.Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob diseasePrions and blood products.Variant Creutzfeldt-Jakob disease: a summary of current scientific knowledge in relation to public healthCan mortality data provide reliable indicators for Creutzfeldt-Jakob disease surveillance? A study in France from 2000 to 2008.Clinical implications of bovine spongiform encephalopathy.IFN-γ differentially modulates memory-related processes under basal and chronic stressor conditions.Species-barrier-independent prion replication in apparently resistant species.The transmissible spongiform encephalopathies: pathogenic mechanisms and strategies for therapeutic intervention.Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-- Jakob disease: implications for human healthEstimation of the exposure of the UK population to the bovine spongiform encephalopathy agent through dietary intake during the period 1980 to 1996.A health impact assessment model for environmental changes attributable to development projects.Molecular neurology of prion disease.Human prion disease and relative risk associated with chronic wasting disease.Identification of multiple quantitative trait loci linked to prion disease incubation period in mice.Is there the potential for an epidemic of variant Creutzfeldt-Jakob disease via blood transfusion in the UK?Managing threats rather than risks in blood transfusion: robust design for a complex system.Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concernsDevelopmental expression of PrP in the post-implantation embryo.The predictability of the epidemic of variant Creutzfeldt-Jakob disease by back-calculation methods.Consumption of bovine spongiform encephalopathy (BSE) contaminated beef and the risk of variant Creutzfeldt-Jakob disease.Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility.A vital fluid: risk, controversy and the politics of blood donation in the era of "mad cow disease".PrPSc binding antibodies are potent inhibitors of prion replication in cell lines.Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: updated, detailed analysis.Short-term projections for variant Creutzfeldt-Jakob disease onsets.BSE safety standards: An evaluation of public health policies of Japan, Europe, and USA.A new human genotype prone to variant Creutzfeldt-Jakob disease.Variant Creutzfeldt-Jakob disease in Australian blood donors: estimation of risk and the impact of deferral strategies.Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy.Implications of BSE infection screening data for the scale of the British BSE epidemic and current European infection levels.Factors determining the pattern of the variant Creutzfeldt-Jakob disease (vCJD) epidemic in the UK
P2860
Q24642582-79253507-1E23-41BB-9CC8-D45C281B4612Q24799671-9489B09B-708E-4D9B-8415-762208C9221EQ24801647-2A5D595B-6A6C-459B-A6C7-BA9C6CFDB887Q24802760-8EE7DD46-CFA6-41E1-806B-104704DFFC48Q26861305-C408BB0B-F76D-4CDB-89F0-DF140443D8BBQ30361341-41E95386-6C34-42D4-82BF-CC7417A3EA38Q33804876-71911F7E-B284-47AC-820E-BAB4EC57B17BQ33925903-1AE18B16-5F95-4315-B575-C1244E7EF81DQ33956087-481FF483-A0C2-4D06-A060-4F4525205E00Q34068016-5EDF41EA-3B1E-43C0-9A14-5FCFF7B4ACE2Q34255643-2E49E506-915D-4D31-B2B9-17AC57F87C04Q34547416-F47D8926-383B-4219-BAA8-225DB0E09DFEQ34685449-63964678-8C32-4651-9EEA-1E614A6C3C9EQ35050425-752A6C17-B3BD-497F-A04A-FC98AC622EAFQ35057650-D3E4BB31-3648-4E1B-8930-33F88B73A384Q35148934-BCAD7D70-E0A4-4714-B1A3-C0351C91561BQ35409146-D8A36A35-499D-485F-93F9-A871F48EE5ECQ35488760-3FC55D34-1D30-41AE-8713-BE8F122B776FQ35792137-7E9B80D1-38D5-47D0-8E68-58F3386C64F8Q35939147-889ADA22-A4F3-4C6F-B6A5-B1CBDA892181Q36638892-DED01FD4-5D71-4577-B32E-9D4D587CF11EQ36640500-D4759AC4-D6E8-4C69-A443-90DBCFB11E85Q37074723-9069E063-DE93-47D2-8CC3-FB57E45059DFQ37252531-34F54145-3FCF-46CF-BD4F-1385AD8EF0CAQ39086176-264AED7C-5A50-465A-A677-09575316591CQ39404292-D1942454-87E4-481A-A259-CBA2BEEB577FQ40306174-A4F5FDCA-18D4-4CE1-9256-ADA37831A11AQ40530739-E8D40BC0-6F65-4D78-8043-A0A3466C31FDQ40558013-5C4ADA70-1B74-4A52-9AFA-2137346F18D8Q40578772-EE9F3261-F056-4709-AF65-126A4160B445Q40578783-4B37AF48-2F01-4234-AF9B-169D5A057524Q42017111-C75B6DFA-241F-4772-88C1-F2AD0DEAB310Q42530495-447B367E-8A22-4C84-B787-AC24A32E0673Q44710463-C94F4616-B34C-403A-88B8-1AC09FBF8058Q44949376-F7821A61-3B65-4891-A229-147F3A3F5A86Q55440421-242A9F60-4652-47F7-A7AF-D31C179D636FQ56830857-84AE2C04-741C-4A9D-A7C9-4A08AF238DB9
P2860
description
article publié dans la revue scientifique Nature
@fr
scientific article published in Nature
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в Nature в серпні 2000
@uk
name
Predicted vCJD mortality in Great Britain
@en
Predicted vCJD mortality in Great Britain
@nl
type
label
Predicted vCJD mortality in Great Britain
@en
Predicted vCJD mortality in Great Britain
@nl
prefLabel
Predicted vCJD mortality in Great Britain
@en
Predicted vCJD mortality in Great Britain
@nl
P2860
P50
P356
P1433
P1476
Predicted vCJD mortality in Great Britain
@en
P2860
P2888
P304
P356
10.1038/35020688
P407
P577
2000-08-10T00:00:00Z
P6179
1010684062